| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
GeneDx Holdings Corp. Class A Common Stock$67.86
+8.39 (+12.89%)
Market Cap
1.75 B
EPS
-0.73
P/E Ratio
-82 $
Value Trade
57.09 M
SEC Financials
Q2 2026Dilution Risk
Revenue
114.44 M
R&D Expenses
19.66 M
Total Assets
481.49 M
Total Liabilities
237.26 M
Equity
244.22 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
132.55 M
Monthly Burn
5.82 M
Runway
22.8 mo
Burn Trend
SEC Filing
Aug 3, 2026
Overview
Volume
1.74 M
52 Week Range
55.17 - 170.87
% held by Insiders
7.67 %
% held by Institutions
118.89 %
Enterprise Value
1.69 B
Total Shares
29.67 M
Short %
21.27 %
Float Shares
22.37 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in WGS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
WGS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-WGS
Aug 3, 2026▲ +12.9%today
GeneDx Reports Second Quarter 2026 Financial Results
GeneDx has announced its financial and operational results for the second quarter of 2026. The report highlights the company's ongoing activities and performance metrics. As a publicly traded entity on Nasdaq, GeneDx's results are of interest to investors and stakeholders in the biopharma sector.
Read more →-WGS
Jul 16, 2026GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026
GeneDx has announced that it will release its financial results for the second quarter of 2026 after the market closes on August 3, 2026. This report is expected to provide insights into the company's performance during this period. The announcement reflects GeneDx's commitment to transparency with its stakeholders.
Read more →-WGS
Jun 16, 2026GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth Former Quest Diagnostics leader joins to fuel operational and commercial execution GAITHERSBURG, Md.
GeneDx has appointed Mark Gardner as President, effective June 15, 2026, to enhance its commercial and operational execution. Gardner, who previously held senior roles at Quest Diagnostics and OmniSeq, brings significant industry experience. CEO Katherine Stueland emphasized the importance of execution as the company enters a growth phase. GeneDx aims to leverage its expansive genomic dataset to advance precision medicine and improve health outcomes in rare diseases.
Read more →-WGS
May 26, 2026GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
GeneDx is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. This event is significant for stakeholders in the healthcare sector, providing a platform for discussions and networking. Further details regarding the company's agenda or focus during the conference are not provided.
Read more →-WGS
May 4, 2026GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook Reported first quarter 2026 revenue of $102.3 million with 27% year-over-year growth in exome and genome revenue Reported exome and genome
GeneDx Holdings Corp. reported its first quarter 2026 results, revealing a revenue of $102.3 million with substantial growth in both exome and genome testing. The company experienced a 34% year-over-year increase in testing volume and has adjusted its 2026 revenue guidance to a range of $475 to $490 million. Despite the positive revenue growth, GeneDx reported an adjusted net loss of $8.2 million and a total operating expense that accounted for 76% of its revenue, suggesting financial challenges ahead. The CEO remained optimistic about future growth and profitability as the company navigates the evolving market for genomic services.
Read more →-WGS
Apr 14, 2026▲ +9.6%on this news
GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026
GeneDx has announced that it will release its financial results for the first quarter of 2026 on May 4, 2026, after market close. A conference call will be held the same day at 4:30 p.m. Eastern Time to discuss these results. The company is recognized for its leadership in rare disease diagnosis and genomic data utilization.
Read more →-WGS
Mar 9, 2026▲ +7.3%on this news
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership
GeneDx announced its participation at the 2026 ACMG Annual Meeting, where it will present 18 abstracts, including platform presentations and poster talks. The research emphasizes advancements in genomic testing, AI-supported interpretation, and the impact of early diagnoses. GeneDx Infinity™, its comprehensive genomic dataset, plays a crucial role in these innovations.
Read more →-WGS
Feb 26, 2026GeneDx to Participate in Upcoming March 2026 Investor Conferences
GeneDx will participate in two upcoming investor conferences in March 2026. The events include a fireside chat on March 2 and a presentation on March 11, both of which will be available via live and archived webcasts. This participation highlights GeneDx's commitment to engaging with investors and showcasing its advancements in genomic diagnostics.
Read more →-WGS
Feb 23, 2026▲ +6.1%on this newsshared move
INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GeneDx Holdings Corp. reported its financial results for Q4 and full year 2025, showcasing strong performance and reaffirming guidance for 2026. The company emphasizes its unique position in the genomic diagnosis market and plans to expand into underpenetrated markets. CEO Katherine Stueland highlighted the company's growth potential and the advantages of their GeneDx Infinity platform.
Read more →-WGS
Feb 4, 2026▼ -10.4%on this news
GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026
GeneDx announced it will release its fourth quarter 2025 financial results on February 23, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results. GeneDx is recognized for its leadership in rare disease diagnosis and has developed advanced genomic testing technologies.
Read more →-WGS
Jan 9, 2026GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset
GeneDx has partnered with Komodo Health to develop a comprehensive longitudinal dataset for rare diseases. This collaboration will integrate GeneDx's extensive genomic data with Komodo's Healthcare Map, enhancing insights into patient journeys. The initiative aims to improve health economics and outcomes research, ultimately benefiting biopharma innovation and patient access to therapies.
Read more →-WGS
Jan 5, 2026GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025
GeneDx has solidified its leadership in rare disease genomics by publishing 79 peer-reviewed studies in 2025, bringing its total to over 1,100. The company's GeneDx Infinity™ dataset, the largest of its kind, supports significant advancements in genomic medicine. Notably, the GUARDIAN study was recognized by JAMA for its impact on newborn screening practices. GeneDx continues to push the boundaries of genomic research, enhancing patient care and diagnosis.
Read more →-WGS
Dec 30, 2025GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference
GeneDx will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. CEO Katherine Stueland is scheduled to speak on January 14 at 3:00 p.m. PT. The company is noted for its leadership in rare disease diagnosis and innovative genomic solutions.
Read more →-WGS
May 9, 2023▼ -5.6%on this news· ran to -22% by day 3
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year Revenue in
GeneDx Holdings Corp. reported a strong financial performance in the first quarter of 2023, with pro forma revenue rising to $40.7 million and a notable increase in whole exome testing revenue. The company's cost mitigation efforts led to a significant cash burn improvement of 31%. Despite a net loss of $60.4 million, GeneDx reaffirmed its full-year guidance for 2023, anticipating revenues between $205 to $220 million. The results indicate a growing adoption of its genomic tests and an improving financial outlook.
Read more →-WGS
Mar 14, 2023Net (decrease) increase in cash, cash equivalents and restricted cash $ (263,166) $ 282,509 $ 3,954 Cash, cash equivalents and restricted cash, at beginning of year 401,469 118,960 115,006 Cash, cash equivalents and rest
GeneDx Holdings Corp. reported its financial results for Q4 and full-year 2022, showing a revenue increase, with a focus on profitable growth strategies. The company has secured $150 million in financing to support operations until profitability is expected in 2025. GeneDx also reiterated its 2023 revenue guidance, anticipating between $205 million and $220 million, while facing significant operational losses. The results reflect the combination of Legacy GeneDx's operations with a renewed emphasis on genomic insights and market expansion.
Read more →-WGS
Jan 12, 2023▲ +11.3%on this news
wgsinvestordec 41st Annual JPMorgan Healthcare Conference
GeneDx presented at the 41st Annual JPMorgan Healthcare Conference, discussing its forward-looking strategies and financial projections for 2023. The company emphasized its commitment to enhancing genomic data utilization in healthcare, which it believes will improve diagnostics and treatment outcomes. However, the presentation included multiple forward-looking statements that carry risks regarding market performance and operational transitions, particularly as GeneDx plans to exit its reproductive health and tumor testing businesses. The uncertainty of future results has been highlighted, along with potential financial needs that could affect operational stability.
Read more →-WGS
Aug 26, 2022Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer Mr. Feeley, former CFO of GeneDx and BioReference Laboratories, will focus on further building profitable growth, efficie
Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer Mr. Feeley, former CFO of GeneDx and BioReference Laboratories, will focus on further building profitable growth, efficiency, and scale at Sema4 STAMFORD, CT - August 26, 2022 - S
Read more →-WGS
May 2, 2022Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms Acquisition creates an AI-driven advanced health intellig
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic tes
Read more →-WGS
Nov 15, 2021Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights 36% increase in test volume (excluding COVID-19 tests) compared to the same period last year 17% growth in revenue (excluding COVID-19 tests) com
Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights 36% increase in test volume (excluding COVID-19 tests) compared to the same period last year 17% growth in revenue (excluding COVID-19 tests) compared to the same period last year Full year 2021 total r
Read more →-WGS
Aug 16, 2021Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights 85% test-volume growth (excluding COVID-19 tests) compared to same period in 2020 Recorded 56% growth in total revenue of $46.9 million Expanded
Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights 85% test-volume growth (excluding COVID-19 tests) compared to same period in 2020 Recorded 56% growth in total revenue of $46.9 million Expanded health system partnerships to include NorthShore Univers
Read more →-WGS
Jul 22, 2021Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic Clinical Data Platform Company Sema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transf
Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic Clinical Data Platform Company Sema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transforming healthcare by applying artificial intelligence and m
Read more →-WGS
Feb 10, 2021Sema4, a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate Growth Transaction combines Sema4's leading AI- and machine learning-powered integrated genomic and c
a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate Growth Transaction combines Sema4's leading AI- and machine learning-powered integrated genomic and clinical open-architecture data platform, with CM Life Sciences,
Read more →-WGS
Oct 26, 2020CM Life Sciences, Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about
CM Life Sciences, Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about October 26, 2020 October 23, 2020 - New York, NY - CM Life Sciences, Inc. (Nasdaq: CMLFU) (the "Company") today announced that holders of the Company's units sold
Read more →-WGS
Sep 4, 2020INDEX TO FINANCIAL STATEMENT Audited Financial Statement for CM Life Sciences, Inc.: Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
TO FINANCIAL STATEMENT Financial Statement for CM Life Sciences, Inc.: Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of September 4, 2020 F-3 Notes to Financial Statement F-4 of Independent Registered Public Accounting Firm the Stockho
Read more →-WGS
Sep 1, 2020CM Life Sciences, Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $385 Million Initial Public Offering New York, NY
Life Sciences, Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $385 Million Initial York, NY - September 1, 2020 - CM Life Sciences, Inc. (the "Company") announced today that it priced its initial public offering of 38,500,00
Read more →Competitive Position
How WGS ranks across every disease it competes inCompetitive Position is a premium feature
See how WGS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial